What one share of Precision Biosciences holds
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure.
Precision Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.22 |
|---|---|
| Profit | −$2.60 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.56 |
| Cash and investments | $3.31 |
| Book value | $1.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $20.70 | −$87.55 | $27.15 | −$125.51 | — | $75.36 |
| 2019 | $764.45 | −$66.35 | $17.62 | −$68.36 | — | $81.11 |
| 2020 | $14.00 | −$62.85 | $2.90 | −$53.28 | — | $25.29 |
| 2021 | $59.06 | −$15.64 | $2.58 | −$8.13 | — | $44.91 |
| 2022 | $8.57 | −$38.10 | $1.13 | −$16.75 | — | $16.34 |
| 2023 | $12.68 | −$15.96 | $0.51 | −$22.41 | — | $4.53 |
| 2024 | $9.98 | $1.04 | $0.04 | −$8.53 | — | $6.87 |
| 2025 | $2.67 | −$3.56 | $0.01 | −$5.14 | — | $3.83 |
Common questions about Precision Biosciences
How much does one share of Precision Biosciences earn?
Over the last 12 months, Precision Biosciences lost $2.60 for each share on $2.22 of sales.
Does Precision Biosciences pay a dividend?
Precision Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Precision Biosciences’s book value per share?
Precision Biosciences’s book value is $1.71 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Precision Biosciences have?
Each share of Precision Biosciences has $3.31 of cash and investments, as of June 30, 2026.
What is Precision Biosciences’s free cash flow per share?
−$2.56 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Precision Biosciences bought back shares?
Precision Biosciences’s share count rose about 2339% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.